Dr. Ioan-Andrei Iliuta

MD, MHScTR, MD, MHScTR

Affiliations: Toronto General Hospital, University Health Network

Hereditary Kidney Disease Fellow, Hereditary Kidney Disease Fellow

Research Interests:

Polycystic Kidney Disease

Brief Bio:

After having received his medical degree at Laval University in 2010, Dr. Iliuta completed residency training in internal medicine (2010-2013) and nephrology (2013-2015) in Quebec City. He then pursued a fellowship in Hereditary Kidney Disease under the supervision of Dr. York Pei at Toronto General Hospital, University Health Network, while undergoing graduate training in the Translational Research Program at the Institute of Medical Science, University of Toronto. His clinical interests range from autosomal dominant polycystic kidney disease to tuberous sclerosis complex and inherited tubulopathies. His current research focuses on investigating novel disease-modifying therapies for the treatment of polycystic kidney disease. In the fall, he will be starting a Ph.D. in Biomedical Science at the University of Toronto, with a focus on the therapeutics of AMP kinase in polycystic kidney disease.

Capstone Project:

Tolvaptan is not able to address existing cyst burden in patients with autosomal dominant polycystic kidney disease (ADPKD).

ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis. Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces further growth of cysts but does not reduce the cyst burden.
Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects. From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!

ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis. Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces further growth of cysts but does not reduce the cyst burden.
Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects. From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!

Twitter Handle:

Linkedin:

https://www.linkedin.com/in/ioan-andrei-iliuta-a60930129/?originalSubdomain=ca

Site URL:

https://www.kidney.ca/dr-ioan-andrei-iliuta-profile